Establishment of a regenerative medicine to accelerate the re-epithelialization in acute or chronic wounds by means of a microskin grafting and administration of Fiblast Spray (bFGF)

Establishment of a regenerative medicine to accelerate the re-epithelialization in acute or chronic wounds by means of a microskin grafting and administration of Fiblast Spray (bFGF) - Establishment of a regenerative medicine to accelerate the re-epithelialization in acute or chronic wounds

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006418

Enrollment

120

Registered

2012-01-01

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute wounds:burns, donor site wounds Chronic wounds:pressure ulcers

Interventions

A group:conservative management, once a day, until completion of the re-epithelialization B group:administration of Fiblast Spray only, once a day, until completion of the re-epithlialization C group:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute wounds:burns, donor site wounds Chronic wounds:pressure ulcers

Exclusion criteria

Exclusion criteria: Patients who have complications of 1) Malignancy, 2) Severe systemic illness affecting the liver, kidney, lung, heart, blood, brain and neurological systems

Design outcomes

Primary

Measure	Time frame
1. Speed of the re-epithelialization (days until completion of the re-epithelialization) 2. Appearance, quality (thickness, viscoelasticity) and contraction rate of the healed skin after completion of the re-epithelialization 3. Histological findings	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026